The limited efficacy of available antidepressant therapies may be due to how they affect the underlying brain network. the purpose of this study was to develop a melancholic MDD biomarker to identify critically important functional connections (fcs), and explore their association to treatments. Resting state fMRI data of 130 individuals (65 melancholic major depressive disorder (MDD) patients, 65 healthy controls) were included to build a melancholic MDD classifier, and 10 FCs were selected by our sparse machine learning algorithm. this biomarker generalized to a drug-free independent cohort of melancholic MDD, and did not generalize to other MDD subtypes or other psychiatric disorders. Moreover, we found that antidepressants had a heterogeneous effect on the identified FCs of 25 melancholic MDDs. in particular, it did impact the fc between left dorsolateral prefrontal cortex (DLpfc)/inferior frontal gyrus (ifG) and posterior cingulate cortex (pcc)/precuneus, ranked as the second 'most important' fc based on the biomarker weights, whilst other eight fcs were normalized. Given that left DLpfc has been proposed as an explicit target of depression treatments, this suggest that the limited efficacy of antidepressants might be compensated by combining therapies with targeted treatment as an optimized approach in the future.
Methods participants and clinical measures. The overview of depression biomarker development is shown in
. 177 patients were recruited at the Hiroshima University Hospital and local clinics (in Hiroshima, Japan) and screened using the M.I.N.I. 26, 27 for a MDD diagnosis with the DSM-IV criteria. Out of them, 118 patients participated in the MRI experiments. Exclusion criteria included current or past manic episodes; psychotic episodes; alcohol dependence or/and abuse; substance dependence or/and abuse; and antisocial personality disorder based on M.I.N.I., change of diagnosis (from unipolar to bipolar depression), MRI scan after more than 2 weeks of medication, fMRI data with excessive head motions based on scrubbing results (see the following section of Neuroimaging data preprocessing and interregional correlations). In addition, as the exclusion criteria at the moment of recruitment at local clinics included: already enough amount of dose and time of one type of antidepressant was administered, more than 2 types of antidepressants were administered for the current episode, had electroconvulsive therapy (ECT), physical disorders which may have any negative effects with SSRI treatments, current pregnancy or breast-feeding, high risk of suicidality judged by the doctor, those who needed to be hospitalized, and those who were not able to understand Japanese expressions. 92 patients with more than mild depressive symptoms (i.e., BDI >= 17) were included in the dataset of training the MDD classifier in the end. Patients had an initial MRI scan before or after starting medication within 0-2 weeks. 171 healthy controls (HCs) were recruited from the local community, interviewed with the M.I.N.I., and none showed any history of psychiatric disorders. Ten subjects out of 165 HCs who participated in the MRI experiment were excluded based on M.I.N.I. and on the quality check of MRI. The data of age and sex matched 92 HCs with no or low depressive symptoms (i.e., BDI <= 10) were used for training classifiers for all MDDs. For development of melancholic MDD biomarker, the data of 65 melancholic MDD patients out of 92 MDDs, and age and sex matched 65 HCs were included (Table 1 and Supplementary Table S1a ). The number of patients and healthy controls were set to be equal, in order to develop a classifier unbiased toward either group. Prior to the administration of any experimental procedure, written informed consent was obtained from all participants. For the training dataset of the all MDD classifier, we used all the melancholic and non-melancholic MDD data collected from four different sites to evaluate the entire heterogeneous depression cohort. For the melancholic MDD classifier, the training dataset was limited to have the subtype of melancholia (based on M.I.N.I.) with moderate depression symptoms+ for patients based on the Beck Depression Inventory 28 (BDI-II score 17 or higher). For scores of the Japanese version of national adult reading test (JART) 29 , which was used to estimate the intelligence quotient (IQ), there were eleven missing data in HCs of the training dataset. Additional details on clinical populations can be found in the Supplementary Table S1a -c. The experiments were carried out in accordance with relevant guidelines and regulations, all our experimental protocols were approved by the Ethics Committee of Hiroshima University, and informed consent was obtained from all subjects.
Figure 1.
The integrated pipeline for depression biomarker development. Patients were recruited from local clinics. Resting-state fMRI and structural T1 data were collected using the identical scanner for each subject. Neuroimaging data analysis including preprocessing, functional correlation, and classifier development were performed by integrated scripts. neuroimaging data preprocessing and interregional correlations. T1-weighted structural image and resting state functional images were preprocessed using SPM8 (Wellcome Trust Centre for Neuroimaging, University College London, UK) on Matlab R2014a (Mathworks inc., Massachusetts, USA). The functional images were preprocessed with slice-timing correction and realignment to the mean image. Then, using the normalization parameters obtained through the segmentation of the structural image aligned with the mean functional image, the fMRI data was normalized and resampled in 2 × 2 × 2 mm 3 voxels. Finally, the functional images were smoothed with an isotropic 6 mm full-width half-maximum Gaussian kernel. After these preprocessing steps, a scrubbing procedure 31 was performed to exclude any volume (i.e., functional image) with excessive head motions, based on the frame-to-frame relative changes in time series data. In order to keep data quality high enough for the subsequent analyses, we only included the subject data with more than 50% of the volumes survived in the time series (see Supplementary Table S3 for a summary of head motion). For each individual, the time course of fMRI data was extracted for each of 137 regions of interests (ROIs), anatomically defined in the Brainvisa Sulci Atlas (BSA; http://brainvisa) 32, 33 covering the entire cerebral cortex. We did not incorporate the cerebellum in the construction of a classifier, because for many participants in site 1, the cerebellum was truncated in their structural and functional images. After applying a band-pass filter (0.008-0.1 Hz), the following nine parameters were linearly regressed out: the six head motion parameters from realignment; the temporal fluctuation of the white matter; that of the cerebrospinal fluid; and that of the entire brain. A pair-wise Pearson correlations between 137 ROIs were calculated to obtain a matrix of 9,316 FCs for each participant. Details of classification algorithm for FC selections were described in the following section.
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Classification algorithm for FC selections. By combining the following two machine learning algorithms, we developed a melancholic MDD classifier with identification of characteristic FCs. As the first algorithm, L1-regularized sparse canonical correlation analysis (L1-SCCA) 34 was applied to reduce the number of features to exclude the effects of nuisance variables (NVs) that may cause catastrophic over-fitting. L1-SCCA excluded the effects of nuisance variables (NVs) including sex, age, and scanner type (i.e., four different scanners with two different manufacturers; see the subsection of Supplementary Information entitled "Feature selection with reduction of nuisance variable effects" for details). As the second algorithm, sparse logistic regression (SLR) 35 was applied to identify small number of features with high contribution to classification. The SLR algorithm decides the final number of features based on the principle of Automatic Relevance Determination (ARD) 36 , completely automatically without any meta-parameter. The method uses a sequential process of nested-feature selection and leave-one-out cross validation (LOOCV) in order to avoid information leakage and over-optimistic results 5 . Our machine learning algorithm was a combination of nested cross validation and LOOCV. In order to have more than twenty subjects per fold, we used 6-fold CV for the melancholic MDD classifier development. At the end of LOOCV, the output of the logistic regression classifier was used to compute the classification accuracy. The stability and robustness of the selection of the FCs in the LOOCV by evaluating their cumulative absolute weights = ∑ = c w ,
where N is the number of LOOCV folds (i.e. the number of subjects), and w k i is the weight associated with the k-th FC during the i-th LOOCV fold. The greater magnitude of c k indicates a more significant contribution by the k-th FC to the classification into melancholic MDD and HC, throughout the LOOCV. The more detailed description of this algorithm with some figures are found in the methods section of the autism spectrum disorder paper 37 . The original code developed for the autism spectrum disorder classification is available as well (for access, please contact the server administrator of ATR Brain Information Communication Research Laboratory: http://asd-classifier@atr.jp).
Generalization to independent cohorts for validation. An independent external validation cohort
was formed at the National Institute of Radiological Sciences in Chiba, Japan. Based on M.I.N.I., the participants (n = 51, Supplementary Table S1b ) were evaluated on lifetime history of psychiatric disorders. None of the MDD patients (n = 11) had comorbid psychiatric disorders, and none of the healthy controls (n = 40) had any somatic, neurological, or psychiatric disorders and no history of current or previous drug abuse. All the participants were antidepressant and antipsychotic drug-free for more than 1 month on the day of MRI scan. All participants provided written informed consent before the study. The study protocol was approved by the Radiation Drug Safety Committee and by the institutional review board of the National Institute of Radiological Sciences, in line with the ethical standards established in the 1964 Declaration of Helsinki and its later amendments. Details of generalization to other psychiatric disorders and statistical methods on examining the changes of each FC with antidepressant treatments are shown in Supplementary Information.
Pharmacological treatment effects. Twenty-five patients with melancholic depression in the training
dataset had an additional MRI scan after 6 weeks of treatment with antidepressants (SSRI; see Supplementary  Table S1c ). Because this is an observational study and not a clinical trial, it was not possible to have a placebo or no treatment control group. Although it was a critical issue, based on our hypothesis, we applied the classifier to this post-treatment dataset to examine if all the identified functional connections would be uniformly resolved following treatment, or whilst some functional connections fully resolve, others do not, or are even worsened by the pharmacological treatments.
Results
Classification of melancholic MDD and generalization to an independent cohort. Classification
was first performed by feature-selection from all 9,316 connections using L1-SCCA and SLR, and then the weighted linear summation (WLS, linear discriminant function) of the identified functional connections was evaluated. First, we tried this algorithm to all MDD (n = 184). However, a leave-one-out cross validation (LOOCV) revealed a classification accuracy of only 60% (AUC 0.62, sensitivity 59%, specificity 62%). Next, we focused on a more drug-responsive subtype, melancholic MDD. Then, the LOOCV result on the melancholic MDD (n = 130, Table 1 ) revealed a classification accuracy of 84% (AUC 0.91, sensitivity 80%, specificity 88%; p = 0.002 with a permutation test). We then tested the classifier on an independent cohort from a different site (n = 51), which revealed an accuracy of 69% (AUC 0.69, sensitivity 64%, specificity 70%; p = 0.040 with a permutation test, Supplementary Fig. S1a-d ). Together, even with the limitation of small sample size, these results provided initial evidence that the classifier was moderately generalizable.
Functional connections underlying classification. We then examined the neural basis of melancholic MDD classifier. The sparse classification algorithm identified 10 functional connections (FCs) as listed in Table 2 . Ten FCs were sorted based on its contribution level. The ROIs included in the identified FCs are shown on a glass brain in Fig. 2a . In the distribution of the cumulative absolute weight (Fig. 2b , see Methods), we found that the identified 10 FCs were indeed the top 10 most important FCs among the 32 FCs that were selected at least once during the LOOCV, indicating the reliability of the FC selection in the present procedure. It was further confirmed that the weights of the identified 10 FCs in the LOOCV were significantly nonzero (two-sided Wilcoxon signed rank test, p < 0.001) demonstrating their important contribution to the classification of melancholic MDD and HC. In order to check for potential scanner or site-related effects, each subject's weighted linear sum (WLS) was colored by site in the histogram of Fig. 2c. top two functional connections with the highest contributions. We found outstanding contributions in the top 2 functional connections. Figure 3a shows the plot of each FC's contribution to the classifier (i.e. multiplication of the classifier weight with the difference of each FC between patient and control groups). These top two FCs share an adjacent and part-overlapping brain region as one end of connection around the left 
Effect of treatment with antidepressants.
A subset of our melancholic MDD cohort (n = 25), who were treated with antidepressants as part of their routine clinical care (i.e., escitalopram in the majority of cases), had a further post-treatment rsfMRI scan at 6-8 weeks to evaluate the effect on functional connectivity. First, across these subjects, both the Beck Depression Inventory-II (BDI) score and the Hamilton Rating Scale for Depression (HAMD) were significantly reduced (Mean(SD): BDI Pre = 19.1 (5.63), BDI Post = 11.3 (5.41), paired t-test results on BDI: p = 7.29 × 10 −7 ; and HAMD Pre = 31.3 (7.48), HAMD Post = 18.7 (12.2), paired t-test results on HAMD: p = 7.26 × 10 −7 ).
Next, we evaluated the specific effect of antidepressant treatment on each FC of the melancholic MDD classifier. Based on the hypothesis that antidepressants would normalize the post-treatment MDDs' FC values closer to those of HCs' , the difference in average FC values between post and pre antidepressant treatment was statistically compared to the difference between healthy control and MDD for each FC (Fig. 3c) . FC values were multiplied by the sign of each weight to keep consistent directions; positive for MDD, negative for HC, and p-values were corrected using FDR. For each connection, p-value using Welch's t test with FDR correction was as follows. FC#1: p = 0.328, FC#2: p = 0.012, FC#3: p = 0.083, FC#4: p = 0.328, FC#5: p = 0.328, FC#6: p = 0.328, FC#7: p = 0.328, FC#8: p = 0.328, FC#9: p = 0.328, FC#10: p = 0.328. The over-representation of the same values is because of the Benjamini-Hochberg FDR correction, and uncorrected p-value for each FC was as follows. FC#1: p = 0.318, FC#2: p = 0.001, FC#3: p = 0.016, FC#4: p = 0.166, FC#5: p = 0.312, FC#6: p = 0.244, FC#7: p = 0.162, FC#8: p = 0.291, FC#9: p = 0.181 FC#10: p = 0.327. We found that all but two of the FCs were shifted in a normalized direction (i.e. in the direction of healthy controls) after the treatment, and the result of uncorrected p-value showed difference of treatment effects on two of the FCs. This could be because of heterogeneous influence of pharmacological treatment instead of regression toward the mean as a temporal change. However, one FC changed significantly in the opposite direction -away from that of healthy controls. Interestingly, this was the FC of left DLPFC and left PCC/Precuneus FC, which had the second highest contribution to the classifier (FC#2, pairwise comparison between the classifier contribution and the change by antidepressant treatments (p = 0.012)). Note that in all panels of Fig. 3c -e, a positive change is in the direction of MDD, and a negative change is towards healthy control: www.nature.com/scientificreports www.nature.com/scientificreports/ this is because we multiply FC or differences of FC with the sign of the classifier weight in the melancholic MDD classifier.
Moreover, results of FC#1 (i.e., SN and ECN connectivity: SN-ECN) and FC#2 (i.e., DMN and ECN connectivity: DMN-ECN) changes with the antidepressant treatment were examined more in detail. In order to show early response and treatment outcome, all four conditions were plotted in Fig. 3d (healthy control (HC): n = 65, 0-2 weeks and 6-8 weeks treatment MDD (Dep0-2w, Dep6-8w for each period): n = 25, and an independent cohort of euthymic MDDs, who were fully remitted following long-term treatment with antidepressants (Euthymic: n = 34, Supplementary Table S1c ). One way ANOVA yielded different significant variation among conditions for each FC (FC#1: F(3,145) = 7.37, p = 0.000, FC#2: F(3,145) = 10.9, p = 0.000). For FC#1, antidepressant treatments reasonably normalized the FC1 towards HC. Tukey's HSD showed significant differences between HC and Dep0-2w (p = 0.008), and Dep0-2w and Euthymic (p = 0.001). The other contrasts were not significant: HC and Dep6-8w (p = 0.137, n.s.), HC and Euthymic (p = 0.999, n.s.), 0-2w and 6-8w (p = 0.331, n.s.), and Dep6-8w and Euthymic (p = 0.173, n.s.). On the other hand, for FC#2, there was no normalization effect observed in Dep6-8w. The same post-hoc test (Tukey's HSD) kept showing significant differences not only between HC and Dep0-2w (p = 0.008), but also between HC and Dep6-8w (p = 0.000). In addition, there were significant differences between euthymic group and Dep0-2w (p = 0.008), and Dep6-8w (p = 0.000) in the same way. The rest of conditions showed no significance: HC and Euthymic (p = 0.971, n.s.), 0-2w and 6-8w (p = 0.606, n.s.).
One might assume that there might be some compensatory relationship between FC#1 and FC#2. That is, more positive value in FC#2 might possibly help to have more negative value in FC#1. The answer was shown in Fig. 3e . No compensatory relationship was observed between FC#1 and FC#2 changes (r = −0.147, p = 0.483, n.s.) Assuming that both FC#1 and FC#2 are equally contributing to prediction of remission, the blue to red gradient 
Application to non-melancholic MDD patients.
In order to examine a degree of diagnostic specificity of the melancholic MDD classifier, we also tested the classifier on 27 non-melancholic MDD and 27 additional control subjects. When it was applied to the non-melancholic MDD group, generalization accuracy was 69% (sensitivity 68%, specificity 71%, and AUC 0.72), suggesting that the classifier might be to some extent specific to melancholic MDD. As shown in the density distributions of the weighted linear sum (WLS), the distribution of melancholic MDD and healthy control were significantly different ( Fig. 4a p = 6.3 × 10-14 , Benjamini-Hochberg-corrected Kolmogorov-Smirnov test), and non-melancholic MDD appeared to be shifted toward the direction of the healthy control group along the axis of the melancholic MDD classifier, but this did not reach significance level (Fig. 4b, p = 0. 14, Benjamini-Hochberg-corrected Kolmogorov-Smirnov test).
Application to treatment-resistant MDD. In addition to the non-melancholic MDD patients, we applied the classifier to an independent cohort of treatment-resistant MDD (16 patients, 16 controls). The accuracy was 72% (sensitivity 69%, specificity 75%, and AUC 0.68) and there was no significant difference between the patient and control distributions (Fig. 4c , p = 0.81, n.s., Benjamini-Hochberg-corrected Kolmogorov-Smirnov test).
Application to other psychiatric disorders. To further evaluate the specificity of the classifier, we utilized two other psychiatric cohorts: autism spectrum disorder (ASD; 74 patients, 36 controls) and Schizophrenia spectrum disorder (68 patients, 102 controls). For the ASD cohort, accuracy was 55% (sensitivity 53%, specificity 61%, and AUC 0.63), and as illustrated in the density distributions, there was no difference between patients and controls ( Fig. 4d , p = 0.97, n.s., Benjamini-Hochberg-corrected Kolmogorov-Smirnov test). In the schizophrenia spectrum disorder cohort, accuracy was 41% (sensitivity 40%, specificity 41%, and AUC 0.44). In fact, the schizophrenia spectrum disorder patients' distribution was located significantly on the opposite side to MDD with respect to healthy control (Fig. 4e , p = 0.08, n.s., Benjamini-Hochberg-corrected Kolmogorov-Smirnov test). Overall, these results support a degree of diagnostic specificity of the melancholic MDD classifier. Generalization of the ASD classifier and the Schizophrenia classifier to our MDD cohort was examined and reported elsewhere 37, 39 .
Discussion
The purpose of this study was to develop a melancholic MDD biomarker, and to explore its sensitivity to treatment. In particular, we aimed to test whether functional connectivity changes were influenced homogenously, or heterogeneously, as a window into understanding why treatments might have a limited effect, and potentially even identifying candidate targets for future treatment. Ten FCs were selected by our sparse machine learning algorithm as the melancholic depression biomarker. The validity of the melancholic MDD biomarker was demonstrated by generalization to a completely independent validation cohort, and its specificity was demonstrated by the following applications of the classifier to other subtypes and psychiatric disorders. Moreover, this study showed that antidepressants had a heterogeneous effect on the functional connectivity underlying depression, and this biomarker allowed us to identify and localize the effect of antidepressant action on different functional connections. Specifically, it was highlighted that the FC with the second highest contribution did not show significant normalization after 6-8 weeks of antidepressant treatments, whereas the rest of the FCs were normalized.
Out of ten FCs, the top two FCs with outstanding contributions in the melancholic depression classifier included the FCs with left IFG in ECN and right DMPFC/FEF/SMA in SN for FC#1, and left DLPFC/IFG in ECN and PCC/Precuneus in DMN for FC#2. Although it is still difficult to define their precise neuropsychological roles in depression, previous studies provide some clues. These regions have been associated with cognitive flexibility, for instance, assessed with reversal learning tasks 40, 41 , in which depression patients typically have functional deficits in. Regarding FC#1 (SN-ECN), previous study showed that increased neural activity in IFG and DMPFC were associated with empathic accuracy with compassion meditation training 42 , and reduced connectivity between DMPFC-IFG was observed in depressed adolescents during cognitive reappraisal of emotional images 43 . In addition, priming-TMS studies shows that the DMPFC has a causal role in forming social-relevant impression including face-adjective pair, and processing verbal emotional stimuli 44, 45 . As for FC#2 (DMN-ECN), bilateral DLPFC/IFG have been associated with attention control and conflict processing 46 , and PCC/Precuneus have been associated with anhedonic depression and anxious arousal 47 .
From a general perspective, the correlation between a drug and a functional connection could arise for any one of three reasons: as a cause, epiphenomenon, or compensation for other changes observed in the disorder. In the case of the left DLPFC/IFG -PCC/Precuneus, the second and third possibilities seem unlikely for the following reasons. The epiphenomena hypothesis assumes that the increase or decrease of FC#2 (DMN-ECN) could occur simultaneously with depressive symptoms but not directly in causal relationships. As a remedy for depression, antidepressant therapy reduces severity of depression (i.e., BDI, HAMD scores). Although this hypothesis predicts decrease in FC#2 (DMN-ECN), this is against our experimental observation (Fig. 3d) . The compensation hypothesis assumes that the FC#2 (DMN-ECN) increase actively compensates deteriorating effects induced by the abnormal changes in other FCs in depression, including FC#1 (SN-ECN) increase. This hypothesis predicts positive correlations between changes in FC#1 (SN-ECN) and FC#2 (DMN-ECN), but we did not observe the predicted positive correlations after antidepressants therapy (Fig. 3e ).
On one of the recently suggested reasons on why antidepressants including SSRI might not seem to affect the FC#2 (DMN-ECN) immediately, there was a review paper pointing a problem of antidepressant treatment using Scientific RepoRtS | (2020) 10:3542 | https://doi.org/10.1038/s41598-020-60527-z www.nature.com/scientificreports www.nature.com/scientificreports/ SSRI 48 . The authors suggested that the depression symptom reduction is not achieved by the direct pharmacological properties of SSRI, but by the brain's compensatory responses to restore homeostasis. That may explain why it takes several weeks to achieve the SSRI treatment response outcome rather than 30 minutes after taking the medicine like aspirin. This hypothesis cannot be directly applied to our fMRI results, because the previous PET study showed human serotonin transporter exists more in midbrain 49 rather than in cerebral cortex. However, it could be indirectly associated with our results, showing that the FC#2 (DMN-ECN) moved to the opposite direction of normalization once, and then gradually coming back to the normalizing direction after entering into the -14) . For other subtypes of MDD and psychiatric disorders, there was no significant difference was observed when the melancholic MDD classifier was applied; (b) non-melancholic MDD (Non Mel. MDD) and HC (p = 0.14), (c) treatment-resistant MDD (Treat. Res. MDD) and HC (p = 0.81), (d) autism and HC (p = 0.97), and (e) schizophrenia and HC (p = 0.08). ***p < 0.001.
Scientific RepoRtS |
(2020) 10:3542 | https://doi.org/10.1038/s41598-020-60527-z www.nature.com/scientificreports www.nature.com/scientificreports/ euthymic state. It is impossible to deny the possibility of placebo effect in this paper, because we do did not have any appropriate control group as this was an observational study, not a clinical trial. The potential confounding component here is the time course effect which would make the FCs to regress toward the mean. Although this is the largest limitation, for example, if our results could just be a placebo effect or due to uniform temporal changes of functional correlations, then, all the functional connections should most probably regress toward the same direction to normalization, as BDI and HAMD depression symptom scores were significantly improved on average. However, our data showed different functional connection changes among the identified 10 FCs as shown in Fig. 3c (eight FCs to normalization, one FC with no change, and one FC to the opposite direction). Therefore, though it is the largest limitation that there is no placebo group in this study, there would be a high possibility that our data were able to examine the functional connection specific pharmacological effects.
In addition to a wealth of correlative evidence that links left dorsolateral prefrontal cortex connections to depression 24, [50] [51] [52] [53] [54] [55] [56] [57] , there is other evidence that suggests an active functional relationship. First, it is an established target for repetitive transcranial magnetic stimulation (rTMS) 58-60 therapy for depression. Second, recent neurofeedback treatment directly targeting FC#2 (DMN-ECN) connectivity has been found to be effective [61] [62] [63] . Therefore although more studies are needed, the current evidence points toward a causal influence of DLPFC connectivity and depression.
Limitations
There were several limitations in this study. Given the highly heterogeneous nature, it is important to note limitations of the interpreting rsfMRI results in depression. First, as a limitation of resting state data, we cannot control some spontaneous thoughts or mental activity, and this also could affect stability of the data. Second, although we specifically focused on melancholic depression and identified 10 FCs, this may still limit high classification accuracy 64 as some previous papers suggest the effectiveness of an additive model of categorical diagnosis and symptom dimensions 65 . In addition, we had a small sample size of independent drug-free cohort (with neither antidepressant nor antipsychotic use for more than one month). The most critical limitation in this study was that antidepressant effects were tested on relatively small size of MDD cohort with pre-and post-treatments, and we did not have a placebo or no-treatment group because of ethical issues and difficulty in recruitment. This needs to be tested on a larger cohort in the future. However, the top two critical FCs with especially high contributions included the brain regions which have been persistently implicated across previous depression studies. Ideally, future studies need to track the longer-term profile of FC#2 (DMN-ECN) in larger data sets. Although FC#2 (DMN-ECN) was still abnormal at 6-8 weeks after antidepressant treatments, it was normalized in the euthymic group, which might include only the patients who are responsive to treatments though.
conclusions
This study provides novel evidence on the importance of the critical functional connection between PCC/ Precuneus and left DLPFC/IFG (DMN-ECN), which did not show any improvement right after the antidepressant treatments. Our data not only validated the development of rsfMRI-based melancholic depression biomarker in understanding mechanisms of disorder and treatment, but also suggested the possibility that combined therapy of antidepressants and targeted neurostimulation/neurofeedback could be an optimal strategy to pursue in the future therapeutic studies.
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